Biomarkers for Alzheimer’s Disease Early Diagnosis
Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10045/109042
Título: | Biomarkers for Alzheimer’s Disease Early Diagnosis |
---|---|
Autor/es: | Ausó-Monreal, Eva | Gómez-Vicente, Violeta | Esquiva, Gema |
Grupo/s de investigación o GITE: | Grupo de Investigación en Alimentación y Nutrición (ALINUT) | Grupo de Óptica y Percepción Visual (GOPV) | Neurobiología del Sistema Visual y Terapia de Enfermedades Neurodegenerativas (NEUROVIS) |
Centro, Departamento o Servicio: | Universidad de Alicante. Departamento de Óptica, Farmacología y Anatomía |
Palabras clave: | Alzheimer’s disease | Biomarkers | Early diagnosis | Biofluids |
Área/s de conocimiento: | Anatomía y Embriología Humana |
Fecha de publicación: | 4-sep-2020 |
Editor: | MDPI |
Cita bibliográfica: | Ausó E, Gómez-Vicente V, Esquiva G. Biomarkers for Alzheimer’s Disease Early Diagnosis. Journal of Personalized Medicine. 2020; 10(3):114. https://doi.org/10.3390/jpm10030114 |
Resumen: | Alzheimer’s disease (AD) is the most common cause of dementia, affecting the central nervous system (CNS) through the accumulation of intraneuronal neurofibrillary tau tangles (NFTs) and β-amyloid plaques. By the time AD is clinically diagnosed, neuronal loss has already occurred in many brain and retinal regions. Therefore, the availability of early and reliable diagnosis markers of the disease would allow its detection and taking preventive measures to avoid neuronal loss. Current diagnostic tools in the brain, such as magnetic resonance imaging (MRI), positron emission tomography (PET) imaging, and cerebrospinal fluid (CSF) biomarkers (Aβ and tau) detection are invasive and expensive. Brain-secreted extracellular vesicles (BEVs) isolated from peripheral blood have emerged as novel strategies in the study of AD, with enormous potential as a diagnostic evaluation of therapeutics and treatment tools. In addition; similar mechanisms of neurodegeneration have been demonstrated in the brain and the eyes of AD patients. Since the eyes are more accessible than the brain, several eye tests that detect cellular and vascular changes in the retina have also been proposed as potential screening biomarkers. The aim of this study is to summarize and discuss several potential markers in the brain, eye, blood, and other accessible biofluids like saliva and urine, and correlate them with earlier diagnosis and prognosis to identify individuals with mild symptoms prior to dementia. |
URI: | http://hdl.handle.net/10045/109042 |
ISSN: | 2075-4426 |
DOI: | 10.3390/jpm10030114 |
Idioma: | eng |
Tipo: | info:eu-repo/semantics/article |
Derechos: | © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
Revisión científica: | si |
Versión del editor: | https://doi.org/10.3390/jpm10030114 |
Aparece en las colecciones: | INV - GOPV - Artículos de Revistas INV - ALINUT - Artículos de Revistas INV - NEUROVIS - Artículos de Revistas |
Archivos en este ítem:
Archivo | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Auso_etal_2020_JPersMed.pdf | 1,04 MB | Adobe PDF | Abrir Vista previa | |
Este ítem está licenciado bajo Licencia Creative Commons